Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

International Journal of Pharmaceutics

Volumn 376, Issue 1-2, 2009, Pages 7-12

  Wilson, C G ^a   O'Mahony, B ^a   Connolly, S M ^a   Cantarini, M V ^b   Farmer, M R ^b   Dickinson, P A ^b   Smith, R P ^b   Swaisland, H C ^b  

^a Bio Images Research Ltd   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Gamma scintigraphy; Gastrointestinal transit; Gefitinib; Iressa

Indexed keywords

GEFITINIB; PENTETATE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; WATER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG LABELING; FILM COATING; GAMMA SCINTIGRAPHY; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH EMPTYING; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADULT; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67349222054     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.04.008     Document Type: Article

References (15)

1. Amidon G.L., Lennernäs H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Bergman E., Forsell P., Persson E.M., Knutson L., Dickinson P., Smith R., Swaisland H., Farmer M.R., Cantarini M.V., and Lennernäs H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int. J. Pharm. 341 (2007) p143-142
3. Borgstrom B., Dahlovist A., Lunh G., and Sjovall J. Studies of the intestinal digestion and absorption in the human. J. Clin. Invest. 36 (1957) 1521-1536
4. Dietrich C.G., Geier A., and Elferink R.P.J.O. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52 (2003) 1788-1795
5. Dressman J.B. Kinetics of drug absorption from the gut. In: Hardy G., Davis S.S., and Wilson C.G. (Eds). Drug Delivery to the Gastrointestinal Tract (1989), Ellis Horwood, Chichester 195-220
6. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 (2000) S73-80
7. Ho N.F.H., Merkle H.P., and Higuchi W.I. Quantitative, mechanistic and physiologically realistic approach to the biopharmaceutical design of oral-drug delivery systems. Drug Dev. Ind. Pharm. 9 (1983) 1111-1184
8. Hoffman A.F., Pressman J.H., Code C.F., and Witztum K.F. Controlled entry of orally administered drugs-physiological considerations. Drug Dev. Ind. Pharm. 9 (1983) 1077-1109
9. Jones H.K., Stafford L.E., Swaisland H.C., and Payne R. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials. J. Pharm. Biomed. Anal. 29 (2002) 221-228
10. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42 (2002) 620-643
11. Pang K.S. Modelling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab. Dispos. 31 (2003) 1507-1519
12. Perkins A.C., Wilson C.G., Frier M., Blackshaw P.E., Juan D., Dansereau R.J., Hathaway S., Li Z., Long P., and Spiller R.C. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal disease and normal control subjects. Aliment. Pharmacol. Ther. 15 (2001) 115-121
13. Swaisland H.C., Smith R.P., Laight A., Kerr D.J., Ranson M., Wilder-Smith C.H., and Duvauchelle T. Single-dose clinical pharmacokinetic studies of gefitinib. Clin. Pharmacokinet. 44 (2005) 1165-1177
14. Swaisland H.C., Cantarini M.V., Fuhr R., and Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin. Pharmacokinet. 45 (2006) 633-644
15. Wilson C.G., Washington N., Greaves J.L., Washington C., Wilding I.R., Hoadley T., and Sims E.E. Predictive modelling of the behaviour of a controlled release buflomedil HCl formulation using scintigraphic and pharmacokinetic data. Int. J. Pharm. 72 (2001) 79-86